---
title: "600713.SH (600713.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600713.SH/news.md"
symbol: "600713.SH"
name: "600713.SH"
parent: "https://longbridge.com/en/quote/600713.SH.md"
datetime: "2026-05-20T10:07:51.368Z"
locales:
  - [en](https://longbridge.com/en/quote/600713.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600713.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600713.SH/news.md)
---

# 600713.SH (600713.SH) — Related News

### [Investment of 120 million yuan was "snatched away," NPGC's layout in the digital pathology track encounters obstacles](https://longbridge.com/en/news/287034388.md)
*2026-05-20T08:45:07.000Z*
> NPGC originally planned to invest 120 million yuan to acquire a 22.5% stake in Jiangfeng Biotech, but the investment pla

### [NPC: Net profit of 625 million yuan in 2025, a year-on-year increase of 9.50%](https://longbridge.com/en/news/282331030.md)
*2026-04-10T10:43:31.000Z*
> NPC announced that in 2025, it will achieve an operating income of 54.963 billion yuan, a year-on-year increase of 2.36%

### [NPC: Progress has been made in the investment cooperation with private equity funds](https://longbridge.com/en/news/279910689.md)
*2026-03-20T08:37:46.000Z*
> NPC has made progress in its cooperation with private equity funds for investment matters, planning to invest CNY 120 mi

### [NPC: Plans to remove some directors from their positions, change the company type, and amend the articles of association](https://longbridge.com/en/news/279910197.md)
*2026-03-20T08:34:24.000Z*
> Nanjing Pharmaceutical announced that it plans to remove Marco Kerschen and Luo Xunjie from their positions as directors

### [NPC undergoes a "major overhaul," with the vice president casting three abstention votes](https://longbridge.com/en/news/279592060.md)
*2026-03-18T11:45:00.000Z*
> On March 16, Nanjing Pharmaceutical held an extraordinary board meeting to carry out a major management overhaul. Direct

### [After the original second shareholder exited, there are differences in the board meeting of NPC: the proposals to remove directors and dismiss executives received abstentions](https://longbridge.com/en/news/279461835.md)
*2026-03-17T15:43:12.000Z*
> At the board meeting of NPC, due to the withdrawal of shareholder Alliance Healthcare, the proposal to dismiss two direc

### [GYBYS: Subsidiary completes acquisition of 11.04% stake in NPC](https://longbridge.com/en/news/277165527.md)
*2026-02-27T08:39:05.000Z*
> Baiyunshan announced that its subsidiary, Guangzhou Pharmaceutical Phase II Fund, has completed the acquisition of 11.04

### [Nanjing Pharmaceutical and others established a private equity investment fund company](https://longbridge.com/en/news/276848359.md)
*2026-02-25T07:23:44.000Z*
> According to the Qichacha APP, recently, Nanjing Pharmaceutical Group Jiangfeng Equity Investment Fund Co., Ltd. was est